$ASND News

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275

Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup

Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia

Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24%

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell Midcap

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With Hypoparathyroidism

Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Why Is Ascendis Pharma Stock Gaining Friday?

Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis Pharma A/S Data From Phase 2 PaTH Forward Study Of TransCon PTH Demonstrates Sustained Efficacy, Safety In Participants With Hypoparathyroidism

Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)